News & Media

Study may inform design of next-generation COVID-19, flu vaccines

WashU Medicine scientists lead two large, multicenter programs to develop vaccines and antibody-based therapies for understudied viruses with pandemic potential, including the three shown above: (left to right) chikungunya, dengue and parainfluenza viruses. The programs are supported by two grants from the National Institute for Allergy and Infectious Diseases (NIAID) totaling more than $30 million […]

School of Medicine scientists are working to design a vaccine that reduces sickness and death caused by all potentially deadly coronaviruses. The research is supported by an $8 million grant from the National Institutes of Health (NIH).

To be effective, boosters should target variants widely different from COVID-19 virus’s original strain Alsoussi WB, Malladi SK, Zhou JQ, Liu Z, Ying B, Kim W, Schmitz AJ, Lei T, Horvath SC, Sturtz AJ, McIntire KM, Evavold B, Han F, Scheaffer SM, Fox IF, Mirza S, Parra-Rodriguez L, Nachbagauer R, Nestorova B, Chalkias S, Farnsworth […]

This episode of ‘Show Me the Science’ details the nasal vaccine developed by WashU Medicine scientists; plus, new mRNA vaccine boosters as cold weather approaches. (Photo: Sarah Moser/Getty Images)

Washington University in St. Louis has licensed the rights to develop, manufacture and commercialize its proprietary COVID-19 nasal vaccine in the United States, Europe and Japan to Ocugen Inc., a U.S.-based biotechnology company. (Photo: Getty Images)

The world’s first nasal vaccine for COVID-19 was approved Tuesday, Sept. 6, in India for emergency use. The vaccine, called iNCOVACC, is based on technology licensed from Washington University in St. Louis and developed in collaboration with Bharat Biotech International Limited in India. (Photo: Getty Images)

This episode of ‘Show Me the Science’ focuses on easily transmissible variants causing another wave of COVID-19 infections.  (Photo: Getty Images)

Washington University School of Medicine in St. Louis is participating in a nationwide phase 2 clinical trial to evaluate whether an investigational omicron-specific booster of the Moderna COVID-19 vaccine is safe and capable of eliciting a strong immune response. (Photo: Getty Images)

Ellebedy says that in the two years since SARS-CoV-2 first appeared, millions of infections and vaccinations have created a baseline of immunity in the population, and that the current surge in omicron infections could have been much worse if the country, and the world, didn’t have that immunity built up. (Photo: Getty Images)

A conversation with two scientists who took part in the global effort. MD/PhD student Rita Chen and Brett Case, PhD, a postdoctoral researcher, work with SARS-CoV-2 under strict biosafety conditions in Michael Diamond’s biosafety level 3 lab. (Photo: Matt Miller; Washington University School of Medicine)

Ellebedy, Turner and colleagues have found that the COVID-19 vaccine triggers the development of an immune structure critical to strong and lasting immunity. (Photo: Matt Miller; Washington University School of Medicine)

New approach enables scientists to see how immune system responds to vaccination. (Photo: Getty Images)

The trial will investigate the effectiveness of different combinations of the antimalarial drugs chloroquine and hydroxychloroquine and the antibiotic azithromycin in treating ill patients infected with the novel coronavirus. (Photo: Getty Images)